Aehr Test Systems Soars 59% on AI Backlog Surge, but 520x Valuation Leaves No Room for Error

NEW YORK, April 10 —

Aehr Test Systems (AEHR) jumped 59.5% to all-time highs after reporting AI-driven backlog surges in Q3 FY2026.

What Actually Happened

The quarterly revenue was weak. That part matters, and most of the celebratory coverage glosses over it. What lit the fuse was backlog: AI chip customers need burn-in and test capacity before they ship, and Aehr's order book apparently swelled enough to convince the market that revenue is a timing issue, not a demand issue.

This is a company with $45mn in TTM revenue trading like it already has multiples of that locked in. The bet is straightforward. As AI chip production scales, every chip needs to be tested, and Aehr sells the machines that do it. The backlog surge suggests customers are placing orders now for capacity they'll need in coming quarters.

The company clearly sees the moment too. Alongside earnings, Aehr established a $60mn at-the-market equity offering program. When a $2bn-ish market cap company sets up a facility to sell that much stock, it tells you two things: management wants capital to invest in growth, and management thinks the stock price is high enough to sell into.

The Catch

A 520x forward P/E is not a valuation. It's a prayer. At $45mn in TTM revenue, Aehr needs to roughly triple or quadruple sales just to get to a P/E ratio that growth investors would consider "expensive" rather than "absurd." Backlog is promising, but backlog is not revenue. Orders can be delayed, reduced, or cancelled.

Then there's the ATM. A $60mn offering program doesn't mean they'll sell $60mn in stock tomorrow, but it does mean every rally from here comes with a seller who has a legal obligation to maximize proceeds. That's a ceiling that gets lower the longer the stock stays elevated. For a stock that just moved 59.5% in a day, the supply overhang is real.

Bottom Line

Aehr is a legitimate AI infrastructure play in a niche most investors ignore: the testing equipment that sits between chip fabrication and deployment. The demand story is credible. The price is not. At 520x forward earnings, you're paying today for revenue that might arrive in 2027 or 2028, and you're doing it alongside a company that just set up a mechanism to dilute you along the way.

This is a name to track, not chase. The number to watch is Q4 FY2026 revenue. If backlog starts converting, the story holds. If it doesn't, 520x is a long way to fall.

Aehr Test Systems doesn't have a Basis Report yet. Generate your free AEHR investment report here for a full breakdown of the financials.

Basis Report does not hold positions in securities discussed. This is not investment advice.